MEMS-based confocal laser scanning fluorescence microscopy for tumor demarcation in oncological surgery

Peter Reinig(Fraunhofer Institute for Photonic Microsystems), Stephan Fricke(Fraunhofer Research Institution for Materials Recycling and Resource Strategies IWKS), Hans-Georg Dallmann(Fraunhofer Institute for Photonic Microsystems), Ulrich Blache(Innovation Cluster (Canada)), Markus Schwarzenberg(Fraunhofer Institute for Photonic Microsystems), Julian Rathert(Helios Klinikum Erfurt), Johannes Ziebarth(Fraunhofer Institute for Photonic Microsystems), Sandy Tretbar(Fraunhofer Research Institution for Materials Recycling and Resource Strategies IWKS), Rüdiger Gerlach(Helios Klinikum Erfurt), Rudolf Herbst(Helios Klinikum Erfurt), Jens Knobbe(Fraunhofer Institute for Photonic Microsystems), Jirí Junek
Unknown
March 7, 2022
10.1117/12.2608547
Cited by 2

Related Papers

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
|The Lancet Oncology|2016|704
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
|PLoS ONE|2015|292
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
|Journal of Clinical Oncology|2019|254
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
|The Lancet|2020|242
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
|European Journal of Cancer|2017|203